Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8,006 Mln
P/E Ratio
--
P/B Ratio
3.22
Industry P/E
--
Debt to Equity
1.15
ROE
-0.37 %
ROCE
-18.95 %
Div. Yield
0 %
Book Value
12.96
EPS
-5.55
CFO
$-634.25 Mln
EBITDA
$-2,561.19 Mln
Net Profit
$-3,070.41 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
EXACT Sciences Corporation (EXAS)
| -18.85 | -0.04 | -17.29 | -28.22 | -9.08 | -9.40 | 7.06 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
EXACT Sciences Corporation (EXAS)
| -23.88 | 49.42 | -36.39 | -41.26 | 43.26 | 46.56 | 19.98 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.21 | 9,808.03 | 20.22 | 23.13 | |
| 302.88 | 8,956.09 | 22.08 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 105.76 | 10,030.35 | 30.81 | 14.16 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with... colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Address: 5505 Endeavor Lane, Madison, WI, United States, 53719 Read more
Chairman of The Board & CEO
Mr. Kevin T. Conroy
Chairman of The Board & CEO
Mr. Kevin T. Conroy
Headquarters
Madison, WI
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of EXACT Sciences Corporation (EXAS) stood at $ 5,928 Mln as on 31-Dec-24
The share price of EXACT Sciences Corporation (EXAS) is $45.60 (NASDAQ) as of 24-Apr-2025 16:00 EDT. EXACT Sciences Corporation (EXAS) has given a return of -9.08% in the last 3 years.
EXACT Sciences Corporation (EXAS) has a market capitalisation of $ 8,006 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of EXACT Sciences Corporation (EXAS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the EXACT Sciences Corporation (EXAS) and enter the required number of quantities and click on buy to purchase the shares of EXACT Sciences Corporation (EXAS).
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Address: 5505 Endeavor Lane, Madison, WI, United States, 53719
The CEO & director of Mr. Kevin T. Conroy. is EXACT Sciences Corporation (EXAS), and CFO & Sr. VP is Mr. Kevin T. Conroy.
There is no promoter pledging in EXACT Sciences Corporation (EXAS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| EXACT Sciences Corporation (EXAS) | Ratios |
|---|---|
|
Return on equity(%)
|
-37.09
|
|
Operating margin(%)
|
-36.4
|
|
Net Margin(%)
|
-37.29
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of EXACT Sciences Corporation (EXAS) was $0 Mln.
$1.51
(
